Cited by 267Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatments

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

Open access

Lopez, O L, Becker, J T, Wahed, A S, Saxton, J, Sweet, R A, Wolk, D A, Klunk, W, DeKosky, S T·2009·Journal of Neurology, Neurosurgery & Psychiatry

DOI 10.1136/jnnp.2008.158964PMC PMC2823571

Open this paper in CoChat — free account

Abstract

BACKGROUND: Patients using cholinesterase inhibitors (ChEIs) have a delay in nursing home (NH) admission compared with those who were not using the medication. There are no long-term studies of the effects of memantine in combination with ChEIs use in Alzheimer disease (AD). This study was conducted to examine the effects of ChEIs and memantine on time to death and time to NH admission. METHODS: Time to NH admission and death was examined in 943 probable AD patients who had at least a 1-year follow-up evaluation. Of these patients, 140 (14.9%) used both ChEIs and memantine, 387 (41%) [corrected] used only ChEIs, and 416 (44.1%) [corrected] used neither. The mean (SD) follow-up time was 62.3 (35.8) months. The analysis was conducted with multivariable Cox proportional hazard models controlling for critical covariates (ie, age, education level, gender, severity of the dementia, hypertension, diabetes mellitus, heart disease, psychiatric symptoms and use of psychotropic medications). RESULTS: Compared with those who never used cognitive enhancers, patients who used ChEIs had a significant delay in NH admission (HR: 0.37, 95% CI 0.27 to 0.49); this effect was significantly augmented with the addition of memantine (HR: 0.29, 95% CI 0.11 to 0.72) (memantine+ChEI vs ChEI alone). ChEIs alone, or in combination with memantine had no significant association on time to death. CONCLUSIONS: This observational study revealed that the addition of the NMDA receptor antagonist memantine to the treatment of AD with ChEI significantly altered the treated history of AD by extending time to nursing home admission.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/jnnp.2008.158964

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
[Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients].
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
VALIDITY OF THE TRAIL MAKING TEST AS AN INDICATOR OF ORGANIC BRAIN DAMAGE
Reitan, R. M. (1958) · Perceptual and Motor Skills · doi:10.2466/pms.1958.8.3.271 · Cited by 8,167

Show all 56 references

Research works printed but not linked: 1

[32]APA Diagnostic and statistical manual on mental disorders—Revised (DSM-III-R) 1987 3rd edn. Washington, DC American Psychiatric Press

Sorted by citations

Alzheimer's disease
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 765
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
The multiplex model of the genetics of Alzheimer's disease
Sims, R., Hill, M., & Williams, J. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0599-5 · Cited by 466
Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis
Toot, S., Swinson, T., Devine, M., Challis, D., & Orrell, M. (2017) · International Psychogeriatrics · doi:10.1017/s1041610216001654 · Cited by 421
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology
O'Brien, J. T., Holmes, C., Jones, M. S., Jones, R. W., Livingston, G., McKeith, I. G., Mittler, P. J., Passmore, P., Ritchie, C. W., Robinson, L. A., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 361
Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
Parsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9398-z · Cited by 346
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
Therapeutics of Neurotransmitters in Alzheimer’s Disease
Kandimalla, R. J. L., & Reddy, P. H. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161118 · Cited by 274
Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease
Noetzli, M., & Eap, C. B. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0038-9 · Cited by 230
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Dysfunctional synapse in Alzheimer's disease – A focus on NMDA receptors
Mota, S. I., Ferreira, I. L., & Rego, A. C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.013 · Cited by 215
Folic Acid Supplementation Mitigates Alzheimer’s Disease by Reducing Inflammation: A Randomized Controlled Trial
Chen, H., Liu, S., Ji, L., Wu, T., Ji, Y., Zhou, Y., Zheng, M., Zhang, M., Xu, W., & Huang, G. (2016) · Mediators of Inflammation · doi:10.1155/2016/5912146 · Cited by 202
Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
Rountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181
Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence
Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses
Howard, R. J., McShane, R. H., Lindesay, J. E. B., Ritchie, C. W., Baldwin, A., Barber, R., Burns, A. S., Dening, T., Findlay, D. M., Holmes, C., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00258-6 · Cited by 171
Update on the Pharmacological Treatment of Alzheimers Disease
Massoud, F., & Gauthier, S. G. (2010) · Current Neuropharmacology · doi:10.2174/157015910790909520 · Cited by 168
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology
O'Brien, J. T., & Burns, A. S. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110387547 · Cited by 166
The synapse as a treatment avenue for Alzheimer’s Disease
Peng, L., Bestard‐Lorigados, I., & Song, W. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01565-z · Cited by 162
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Grossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151
EFNS ‐ ENS / EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease
Schmidt, R., Hofer, E., Bouwman, F. H., Buerger, K., Cordonnier, C., Fladby, T., Galimberti, D., Georges, J., Heneka, M. T., Hort, J., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12707 · Cited by 140
Tau‐targeted treatment strategies in Alzheimer's disease
Götz, J., Ittner, A., & Ittner, L. M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01713.x · Cited by 130
The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease
Deardorff, W. J., Feen, E. S., & Grossberg, G. T. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0273-x · Cited by 136
Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Are Irreversible Inhibitors the Future?
Moss, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103438 · Cited by 138
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt160 · Cited by 126
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
Deardorff, W. J., & Grossberg, G. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86463 · Cited by 125
Treatment for Alzheimer's disease
Fox, N. C., Belder, C. R. S., Ballard, C. G., Kales, H. C., Mummery, C. J., Caramelli, P., Ciccarelli, O., Frederiksen, K. S., Gómez‐Isla, T., Ismail, Z., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01329-7 · Cited by 137
Current therapeutic targets for the treatment of Alzheimer’s disease
Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 123
Department of Neurology
Bojar, M. (2009) · Cited by 120
Predictors of Institutionalization of Dementia Patients in Mild and Moderate Stages: A 4-Year Prospective Analysis
Eska, K., Graessel, E., Donath, C., Schwarzkopf, L., Lauterberg, J., & Holle, R. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000355079 · Cited by 119
Slowing the progression of Alzheimer’s disease; what works?
Nelson, L., & Tabet, N. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.07.002 · Cited by 117
Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease
Gauthier, S. G., & Molinuevo, J. L. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.11.005 · Cited by 111
Present Algorithms and Future Treatments for Alzheimer’s Disease
Grossberg, G. T., Tong, G., Burke, A. D., & Tariot, P. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180903 · Cited by 111
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
Rountree, S. D., Atri, A., Lopez, O. L., & Doody, R. S. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.01.002 · Cited by 97
Combination Therapy for Alzheimerʼs Disease
Patel, L., & Grossberg, G. T. (2011) · Drugs & Aging · doi:10.2165/11591860-000000000-00000 · Cited by 95
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 99
Memantine
McKeage, K. (2009) · CNS Drugs · doi:10.2165/11201020-000000000-00000 · Cited by 85
Very Mild to Severe Dementia and Mortality: A 14-Year Follow-Up – The Odense Study
Andersen, K., Lolk, A., Martinussen, T., & Kragh-Sørensen, P. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000265553 · Cited by 82
Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer DiseasePreprint
Aisen, P. S. S., Cummings, J. L., & Schneider, L. S. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006395 · Cited by 83
Alzheimer’s Disease Therapeutic Approaches
Revi, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32633-3_15 · Cited by 84
Predictors of long-term cognitive outcome in Alzheimer's disease
Wattmo, C., Wallin, Å. K., Londos, E., & Minthon, L. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt85 · Cited by 81
Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
Atri, A., Hendrix, S. B., Pejović, V., Hofbauer, R. K., Edwards, J., Molinuevo, J. L., & Graham, S. M. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0109-2 · Cited by 78
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders
Malar, D. S., Thitilertdecha, P., Ruckvongacheep, K. S., Brimson, S., Tencomnao, T., & Brimson, J. M. (2023) · CNS Drugs · doi:10.1007/s40263-023-01007-6 · Cited by 77
Factors that influence survival in a probable Alzheimer disease cohort
Rountree, S. D., Chan, W., Pavlik, V., Darby, E. J., & Doody, R. S. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt119 · Cited by 72
Efficacy of Memantine, Donepezil, or Their Association in Moderate‐Severe Alzheimer’s Disease: A Review of Clinical Trials
Molino, I., Colucci, L., Fasanaro, A. M., Traini, E., & Amenta, F. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/925702 · Cited by 73
Use of memantine for the treatment of dementia
Lo, D. T., & Grossberg, G. T. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.132 · Cited by 71
Memantine ER/Donepezil: A Review in Alzheimer’s Disease
Greig, S. L. (2015) · CNS Drugs · doi:10.1007/s40263-015-0287-2 · Cited by 69
Memantine in dementia: a review of the current evidence
Herrmann, N., Li, A., & Lanctôt, K. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.558006 · Cited by 71
A review of the effects of memantine on clinical progression in Alzheimer's disease
Wilkinson, D. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2788 · Cited by 74
Alzheimer’s Disease: A Clinical Practice-Oriented Review
Alves, L., Correia, A. S., Miguel, R., Alegria, P., & Bugalho, P. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00063 · Cited by 74
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study
Choi, S. H., Park, K. W., Na, D. L., Han, H. J., Kim, E., Shim, Y. S., Lee, J., & The EXPECT Study Group (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.582484 · Cited by 69
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Giovanni, G. D., Štrac, D. Š., Solé, M., Unzeta, M., Tipton, K. F., Mück‐Šeler, D., Bolea, I., Corte, L., Perković, M. N., Pivac, N., et al. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00541 · Cited by 76
Effect of Memantine on Resting State Default Mode Network Activity in Alzheimerʼs Disease
Lorenzi, M., Beltramello, A., Mercuri, N. B., Canu, E., Zoccatelli, G., Pizzini, F. B., Alessandrini, F., Cotelli, M., Rosini, S., Costardi, D., et al. (2011) · Drugs & Aging · doi:10.2165/11586440-000000000-00000 · Cited by 64
Long‐term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease
Zhu, C. W., Livote, E. E., Scarmeas, N., Albert, M., Brandt, J., Blacker, D., Sano, M. C., & Stern, Y. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.09.015 · Cited by 67
Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Tonda‐Turo, C., Origlia, N., Mattu, C., Accorroni, A., & Chiono, V. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180221125759 · Cited by 61
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 61
An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease
Calhoun, A. J., King, C., Khoury, R., & Grossberg, G. T. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519022 · Cited by 62
Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS
Spackman, E., Kadiyala, S., Neumann, P. J., Veenstra, D. L., & Sullivan, S. D. (2012) · Current Alzheimer Research · doi:10.2174/156720512803569046 · Cited by 59
The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease
Cappell, J., Herrmann, N., Cornish, S., & Lanctôt, K. L. (2010) · CNS Drugs · doi:10.2165/11539530-000000000-00000 · Cited by 57
Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland
Taipale, H. T., Tanskanen, A. J., Koponen, M., Tolppanen, A., Tiihonen, J., & Hartikainen, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000032 · Cited by 56
Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer’s disease dementia
Belger, M. A., Haro, J. M., Reed, C. C., Happich, M., Argimón, J. M., Bruno, G., Dodel, R. C., Jones, R. W., Vellas, B. J., & Wimo, A. B. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-018-1001-3 · Cited by 55
Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development
Savonenko, A. V., Melnikova, T., Hiatt, A., Li, T., Worley, P. F., Troncoso, J. C., Wong, P. C., & Price, D. L. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.211 · Cited by 52
Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects
Rajput, A., Pingale, P., & Dhapte-Pawar, V. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.979682 · Cited by 54
Management of patients with Alzheimer’s disease: pharmacological treatment and quality of life
Mossello, E., & Ballini, E. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312452387 · Cited by 51
Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer’s Disease and Other Dementias
Muayqil, T. A., & Camicioli, R. M. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000343479 · Cited by 48
Memantine in Patients with Moderate to Severe Alzheimer's Disease: Meta-Analyses Using Realistic Definitions of Response
Wilkinson, D. G., Wirth, Y., & Goebel, C. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000353801 · Cited by 47
Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer’s Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine
Doody, R. S., Geldmacher, D., Farlow, M. R., Sun, Y., Moline, M. L., & Mackell, J. A. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000338236 · Cited by 47
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease
Nirogi, R. V. S., Shinde, A. K., Kambhampati, R. S., Mohammed, A. R., Saraf, S. K., Badange, R. K., Bandyala, T. R., Bhatta, V., Bojja, K., Reballi, V., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01662 · Cited by 47
Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction
Moss, D. E., & Perez, R. G. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666211215150547 · Cited by 48
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia
Parsons, C., Lim, W. Y., Loy, C. T., McGuinness, B., Passmore, P., Ward, S. A., & Hughes, C. M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009081.pub2 · Cited by 49
Effectiveness and Cost-Effectiveness of the Pharmacological Treatment of Alzheimer's Disease and Vascular Dementia
Versijpt, J. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132639 · Cited by 48
A population-based study of dosing and persistence with anti-dementia medications
Brewer, L., Bennett, K., McGreevy, C., & Williams, D. J. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1483-y · Cited by 45
Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer’s disease
Francis, P. T., Parsons, C. G., & Jones, R. W. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.124 · Cited by 47
Alzheimer Disease Pharmacologic Treatment and Treatment Research
Schneider, L. S. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429180.60095.d0 · Cited by 45
Retrospective Study on the Benefits of Combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: The MEMAGE Study
Gareri, P., Putignano, D., Castagna, A., Cotroneo, A. M., Palo, G. D., Fabbo, A., Forgione, L., Giacummo, A., Lacava, R., Marino, S., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132735 · Cited by 42
Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease
Chiu, M., & Fan, L. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s45143 · Cited by 41
Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease.
Shao, Z. (2015) · PubMed Central · Cited by 40
A task force for diagnosis and treatment of people with Alzheimer’s disease in Latin America
Lopera, F. J., Custodio, N., Rico-Restrepo, M., Allegri, R., Barrientos, J. D., Batres, E. G., Calandri, I. L., Moscoso, C., Caramelli, P., Quiroz, J. C. D., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1198869 · Cited by 42
Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease
de Oliveira, F. F., Bertolucci, P. H. F., Chen, E., & Smith, M. D. A. C. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.10.015 · Cited by 36
NMDA receptors mediate synaptic depression, but not spine loss in the dentate gyrus of adult amyloid Beta (Aβ) overexpressing mice
Müller, M., Jacobi, E., Sakimura, K., Malinow, R., & von Engelhardt, J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0611-4 · Cited by 40
Cholinesterase Inhibitor and Memantine Use in Newly Admitted Nursing Home Residents with Dementia
Parsons, C., Briesacher, B. A., Givens, J. L., Chen, Y., & Tjia, J. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03478.x · Cited by 37
Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?
Sequeira, L., Benfeito, S., Fernandes, C., Gaspar, A., Lima, I., Peixoto, J., Alves, C., Machado, C. S., Borges, F., & Chavarria, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060708 · Cited by 37
Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors
Shi, X., Lin, X., Hu, R., Sun, N., Hao, J., & Gao, C. (2016) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317515622283 · Cited by 36
Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine
Wong, C. W. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0372-3 · Cited by 37
The Role of Phosphodiesterase-2 in Psychiatric and Neurodegenerative Disorders
Zhang, C., Lueptow, L. M., Zhang, H., O’Donnell, J. M., & Xu, Y. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-58811-7_12 · Cited by 35
Prediction of general hospital admission in people with dementia: Cohort study
Russ, T. C., Parra, M. A., Lim, A. E., Law, E., Connelly, P., & Starr, J. M. (2014) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.137166 · Cited by 34
Neuropsychological assessments of cognitive aging in monolingual and bilingual older adults
Anderson, J. A. E., Saleemi, S., & Bialystok, E. (2016) · Journal of Neurolinguistics · doi:10.1016/j.jneuroling.2016.08.001 · Cited by 40
Somatic comorbidities and Alzheimer’s disease treatment
Clodomiro, A., Gareri, P., Puccio, G., Frangipane, F., Lacava, R. V., Castagna, A., Manfredi, V. G. L., Colao, R., & Bruni, A. C. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1290-3 · Cited by 35
The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France
Touchon, J., Lachaîne, J., Beauchemin, C., Granghaud, A., Rive, B., & Bineau, S. (2013) · The European Journal of Health Economics · doi:10.1007/s10198-013-0523-y · Cited by 33
Combined treatment with memantine/es‐citalopram for older depressed patients with cognitive impairment: a pilot study
Pelton, G. H., Harper, O. L., Roose, S. P., Marder, K. S., D’Antonio, K., & Devanand, D. P. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4375 · Cited by 32
Validity of a Novel Touch Screen Tablet-Based Assessment for Mild Cognitive Impairment and Probable AD in Older Adults
Huang, Y.-P., Ningthoujam, A. S., Chen, S., Sun, F., Huang, C., & Liu, S. (2017) · Assessment · doi:10.1177/1073191117748395 · Cited by 29
Memantine Extended Release (28 mg Once Daily): A Review of Its Use in Alzheimer’s Disease
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0400-3 · Cited by 32
Hydrazone–Sulfonate Hybrids as Potential Cholinesterase Inhibitors: Design, Synthesis and Molecular Modeling Simulation
Omar, M. A., El‐Shiekh, R. A., Dawood, D. H., Temirak, A., & Srour, A. M. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0238 · Cited by 29
Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease
Deardorff, W. J., & Grossberg, G. T. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1215431 · Cited by 28
Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer’s Disease
Li, Q., Rubin, L., Silva, M., Li, S., Yang, C., Lazarovici, P., & Zheng, W. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3777021 · Cited by 28
Activation of Brain Histaminergic Neurotransmission: A Mechanism for Cognitive Effects of Memantine in Alzheimer’s Disease
Motawaj, M., Burban, A., Davenas, E., & Arrang, J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174458 · Cited by 27
Ethical issues in Alzheimer’s disease: an overview
Leuzy, A., & Gauthier, S. G. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.38 · Cited by 27
Cost‐effectiveness of memantine in moderate and severe Alzheimer's disease in Norway
Rive, B., Aarsland, D., Grishchenko, M., Cochran, J. M., Lamure, M. P., & Toumi, M. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2755 · Cited by 26
The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan
Wu, C.-Y., Hu, H.-Y., Chow, L., Chou, Y., Huang, N., Wang, P., & Li, C.-P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130993 · Cited by 26

Authors: Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T.
Affiliations: University of Pittsburgh (US)
ORCID: Becker, J T
Wahed, A S
Sweet, R A
Wolk, D A
Klunk, W
DeKosky, S T
Venue: Journal of Neurology, Neurosurgery & Psychiatry
Publisher: BMJ
Published: 2009-02-09
Volume: 80
Issue: 6
Pages: 600-607
ISSN: 0022-3050 (ISSN-L)
DOI: 10.1136/jnnp.2008.158964
PMC: PMC2823571
OpenAlex: W2171545307
Cited by: 266
References: 56
Citations by year: 2026: 6 · 2025: 7 · 2024: 10 · 2023: 5 · 2022: 9 · 2021: 5 · 2020: 11 · 2019: 7 · 2018: 14 · 2017: 14 · 2016: 18 · 2015: 26 · 2014: 18 · 2013: 25 · 2012: 30
FWCI: 18.51
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
HighWire Press Open Archive (submittedVersion)
Funders: National Institutes of Health (5p01ag003705-04)
National Institute on Aging (AG 05-133, AG 20098, AG027224, P50AG005133, U01AG016976, AG 03705, R01AG020098, AG-16976, R56AG020098, R01AG027224)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: Alzheimer's disease, memantine, cholinesterase inhibitors, combination therapy, nursing home admission, time to death, NMDA receptor antagonists, long-term effects
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Drug Therapy, Combination, Female, Follow-Up Studies, Homes for the Aged, Humans, Male, Memantine, Mental Status Schedule, Neuropsychological Tests, Nursing Homes, Patient Admission, Survival Analysis, Excitatory Amino Acid Antagonists, Nootropic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks